The technology developed by Cebiotex in collaboration with academic institutions is a local drug delivery system based on polymeric fibres. Owned platform technology can be applied in multiples medical applications where a local active compound release is clearly beneficial for patient outcome. When an oncological surgeon removes a cancer tumour, there is a medical need to ensure the surgical site is free from cancer cells. During 3-4 weeks after the procedure neither radiotherapy, nor chemotherapy treatments can be applied in order to allow for scarring of the wound. These 3-4 weeks are crucial because, if cancer cells are left, they can reproduce quickly, re-growing the tumour, which may later be hard to contain with radio or chemotherapy Cebiotex nano fibre material allows for highly targeted delivery of the drug. Following surgical removal of resectable tumours, we are targeting the application of our nano-material embedded with a strong antitumoral drug to the bed of the wound. In this way, we carry out sustained delivery of the drug directly at the surgical site during the post operation period when cancer re-growth can occur. Moreover, we avoid blood delivery of the drug avoiding the wide spread toxic effects that this would otherwise generate. Cebiotex technology is initially focused to drug development in the oncology field. However, the same concept will apply to develop novel medical products with other applications as is detailed in the Feasibility Study (confidential information). So, the business strategy of the company is oriented to develop our Business Model based in 2 different product lines, one of them addressed to the oncology market and clients and the other one we have to kept confidential at this stage of development.
These products are important for the current cancer treatment standards because they focus on a non-covered period between tumour resection and subsequent chemotherapy and/or radiotherapy, where the technology of Cebiotex can help to reduce or even stop tumoral cells growth. Therefore, the expected impact for the society is a noticeable higher success expectations in the treatment of the target cancer types.
The overall objectives of the project have been:
- Create a thorough business plan for creating a Nano-tech drug delivery company
- Ensure wide European interest for our company & initial solution within the target sectors and Specialist Hospitals
- Fully understand requirements for moving the first product of the company to and through PHASE 1 (Human) medical trials
